Chronic immune thrombocytopenic purpura: New agents

Hamostaseologie

Volumn 29, Issue 1, 2009, Pages 76-79

  Rodeghiero, Francesco ^a   Ruggeri, M ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Immune thrombocytopenia; Therapy; Thrombopoietin receptor agonist

Indexed keywords

AKR 501; CD20 ANTIBODY; CORTICOSTEROID; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; THROMBOPOIETIN;

BLEEDING; CHRONIC DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION COMPLICATION; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; REVIEW; RISK FACTOR; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 59649121334     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616946     Document Type: Review

References (47)

1. Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, oral, nonpeptide thrombopoietin receptor agonist. Bood 2007; 109: 4739-4741.
2. Kumagai Y, Fujita T, Okazi M et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis - stimulating peptibody in healty Japanese subjects: a randomized , placebo-controlled study. J Clin Pharmacol 2007; 47: 1489-1497.
3. Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis - stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681.
4. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135: 547-553.
5. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic Purpura. N Engl J Med 2007; 357: 2237-2247.
6. Kuter DJ, Bussel JB, Lyons RM et al. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. Lancet 2008; 371: 395-403.
7. Ballem PA, Segal GM, Stratton JR et al. Mechanism of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence for both impaired platelet production and incresed platelet clearance. J Clin Invest 1987; 80: 33-40.
8. Gernsheimer T, Stratton J, Ballem Pj, Slichter SJ. Mechanism of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989; 320: 974-980.
9. Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985; 312: 1170-1174.
10. Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895.
11. Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-706.
12. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol Basel 1958; 20: 350-355.
13. Vigon I, Mornon JP, Cocaut L et al. Molecular cloning and characterization of MPL, the human homology of the v-mpl oncogene: identification of a member of the hemopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89: 5640-5644.
14. de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994; 369: 533-538.
15. Lok S,Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-568.
16. Wenlding F, Maraskovky E, Debili N et al. CMPL ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-574.
17. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
18. Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol 2008; 69 (Suppl): 9-18.
19. Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007; 44: S35-S45.
20. George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93: 1445-1449.
21. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-912.
22. Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-442.
23. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
24. British Committee for Standards in Haematology General Haematology Task Force.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596.
25. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura. Blood 2005; 106: 2244-2251.
26. Cheng Wong R, Yoo J, Chui C et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836.
27. Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401-1407.
28. Neylon AJ, Saunders PWG, Howard MR et al. Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-974.
29. Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand H. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
30. Cortelazzo S, Finazzi G, Buelli M et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31-33.
31. Kojouri K, Vesely SK, Terrel DR et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.
32. Sailer T, Lechner K, Panzer S et al. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006; 91: 1041-1045.
33. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104: 956-960.
34. Firkin BG, Hunt HA, Jane SM. Management of refractory idiopathic thrombocytopenia. Blood Rev 1988; 2: 149-156.
35. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309-2317.
36. Manoharan A. Treatment of refractory idiopathic thrombocytopenic purpura in adults. Br J Haematol 1991; 79: 143-147.
37. Mc Millan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997; 126: 307-314.
38. Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002; 16: 31-36.
39. Provan D. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118: 933-944.
40. Vesely SK, Erdue JJ, Rizvi MA et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Int Med 2004; 140: 112-120.
41. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143: 16-26.
42. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 12: 1630-1638.
43. Cooper N, Woloski BM, Fodero EM et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002; 15: 1922-1927.
44. George JN, Raskob GE, Vesely SK. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003; 74: 161-169.
45. Arnold D, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
46. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
47. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-1537.